Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.

Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S.

AIDS. 2009 Jan 28;23(3):426-8. doi: 10.1097/QAD.0b013e328321305a.

PMID:
19114866
2.

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.

Pujades-Rodríguez M, Schramm B, Som L, Nerrienet E, Narom P, Chanchhaya N, Ferradini L, Balkan S.

Trop Med Int Health. 2011 Feb;16(2):205-13. doi: 10.1111/j.1365-3156.2010.02689.x. Epub 2010 Nov 19.

3.
4.

Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.

Borget MY, Diallo K, Adje-Toure C, Chorba T, Nkengasong JN.

J Clin Virol. 2009 May;45(1):72-5. doi: 10.1016/j.jcv.2009.03.011. Epub 2009 Apr 17.

PMID:
19375979
5.

Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.

Sarfo FS, Bibby DF, Schwab U, Appiah LT, Clark DA, Collini P, Phillips R, Green I, Dittmar MT, Chadwick DR.

J Antimicrob Chemother. 2009 Sep;64(3):667-9. doi: 10.1093/jac/dkp216. Epub 2009 Jun 23. No abstract available.

PMID:
19549668
6.

Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.

Rodés B, Toro C, Jiménez V, Soriano V.

Clin Infect Dis. 2005 Jul 15;41(2):e19-21. Epub 2005 May 31.

PMID:
15983906
7.

[Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study].

Ndour CT, Batista G, Manga NM, Guèye NF, Badiane NM, Fortez L, Sow PS.

Med Mal Infect. 2006 Feb;36(2):111-4. Epub 2006 Feb 15. French.

PMID:
16480843
8.

[Detection of the viral load and its use as a virological marker in the follow-up of HIV-1-positive patients].

Hodara VL, Monticelli A, Benetucci J, Lasala M, Jauregui Rueda H, Libonatti O, García Messina O, Reboredo G, Bogdanowicz E, Bases O, Pampuro S, Salomón H.

Rev Argent Microbiol. 1998 Jan-Mar;30(1):1-7. Spanish.

PMID:
9629601
9.

Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario.

Tumbarello M, Rabagliati R, De Gaetano Donati K, Bertagnolio S, Tamburrini E, Tacconelli E, Cauda R.

AIDS. 2003 Jan 3;17(1):128-31. No abstract available.

PMID:
12478081
10.

Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003).

Sued O, Miró JM, Alquezar A, Claramonte X, García F, Plana M, Arnedo M, de Lazzari E, Gil C, Manzardo C, Blanco JL, Martínez E, Mallolas J, Joseph J, Pumarola T, Gallart T, Gatell JM.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):238-44.

PMID:
16725083
11.

The development of artificial neural networks to predict virological response to combination HIV therapy.

Larder B, Wang D, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, Monforte AD, Torti C, Zazzi M, Lane C.

Antivir Ther. 2007;12(1):15-24.

PMID:
17503743
12.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

PMID:
19420019
13.

Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.

Hasson H, Mantelli B, Biswas P, Malnati M, Gianotti N, Vecchi A, Nozza S, Cernuschi M, Boeri E, Clerici M, Lazzarin A, Beretta A.

J Med Virol. 2007 Nov;79(11):1640-9.

PMID:
17854028
14.

Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).

Avettand-Fenoel V, Bouteloup V, Mélard A, Fagard C, Chaix ML, Leclercq P, Chêne G, Viard JP, Rouzioux C; members of the ETOILE study.

J Antimicrob Chemother. 2010 Oct;65(10):2212-4. doi: 10.1093/jac/dkq282. Epub 2010 Jul 28.

PMID:
20667886
15.

HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.

Kolte L, Ryder LP, Albrecht-Beste E, Jensen FK, Nielsen SD.

Scand J Immunol. 2009 Dec;70(6):608-13. doi: 10.1111/j.1365-3083.2009.02328.x.

16.

Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone.

Paparizos VA, Kyriakis KP, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):257-8. No abstract available.

PMID:
12045689
17.

Factors associated with incomplete virological response to highly active antiretroviral therapy.

Welch K, Morse A, Clark R, Ogbuokiri T.

Clin Infect Dis. 2000 Feb;30(2):407-8. No abstract available.

PMID:
10671360
18.

HIV type 2 demyelinating encephalomyelitis.

Moulignier A, Lascoux C, Bourgarit A.

Clin Infect Dis. 2006 Jun 1;42(11):e89-91. Epub 2006 Apr 26.

PMID:
16652302
19.

[Viral loads in pediatric HIV patients with antiretroviral treatment].

Porto-Espinoza L, Moronta R, Cuadra-Sánchez C, Callejas-Valero D, Costa-León L, Monsalve-Castillo F, Bernardoni C, Estévez J.

Rev Med Chil. 2008 Aug;136(8):1021-6. doi: /S0034-98872008000800009. Epub 2008 Oct 7. Spanish.

20.

Immunological changes during treatment interruptions: risk factors and clinical sequelae.

Poulton MB, Sabin CA, Fisher M.

AIDS. 2003 Jan 3;17(1):126-8. No abstract available.

PMID:
12478080

Supplemental Content

Support Center